Kidney Failure, Chronic
Pipeline by Development Stage
Drug Modality Breakdown
Nephrology is a $36.6B mature market dominated by cardiometabolic crossover drugs with limited pure renal innovation.
Key Trends
- GLP-1 agonists and SGLT2 inhibitors dominate (69% of spending) due to dual cardio-renal benefits
- Patent cliffs approaching 2026-2030 create generic conversion risk for blockbuster franchises
- Pipeline activity remains robust (2,785 trials) but concentrated in early-phase basic research
Career Verdict
Nephrology offers stable employment in commercial and medical affairs roles, but limited growth upside due to mature blockbuster dependency and declining pure renal research focus.
AI-generated market analysis based on FDA, CMS, ClinicalTrials.gov, and hiring data
Market Leaders
| # | Product | Company | Revenue | Share | Stage | Trend | LOE |
|---|---|---|---|---|---|---|---|
| 1 | OZEMPIC (semaglutide) | Novo Nordisk | $9.2B | 25% | Peak | Stable | 12.4yr |
| 2 | JARDIANCE (empagliflozin) | Boehringer Ingelheim | $8.8B | 24% | Peak | Stable | 8.6yr |
| 3 | TRULICITY (dulaglutide) | Eli Lilly and Company | $7.4B | 20% | Peak | Stable | |
| 4 | FARXIGA (dapagliflozin) | AstraZeneca | $4.3B | 12% | Peak | Stable | 15.4yr |
Drug Class Breakdown
cardiometabolic dominance
cardioprotective expansion
heart failure crossover
overactive bladder niche
declining relevance
Career Outlook
StableNephrology careers are stable but not expanding; the field is supported by blockbuster drugs (GLP-1s, SGLT2i) that face patent cliffs between 2026–2041, creating near-term employment security but long-term uncertainty. Commercial and medical affairs roles dominate hiring, while R&D investment is limited to niche mechanisms (complement inhibition, gene therapy). Career progression depends on specialization in medtech, diagnostics, or orphan nephrology rather than traditional pharma blockbuster development.
Breaking In
Target medtech platforms (Outset, Fresenius) or biotech innovators (Vertex, Calyxo) over traditional pharma; nephrology offers job stability and clinical depth but limited growth trajectory in pure pharmaceutical roles.
For Experienced Professionals
Leverage cardiometabolic expertise to span diabetes, CKD, and HF franchises; position for transition to orphan nephrology (ADPKD, FSGS, IgA) where innovation and valuation multiples are highest.
In-Demand Skills
Best For
Hiring Landscape
Nephrology hiring is concentrated in commercial roles (58 positions, $108K avg) and medical affairs (12 positions, $330K avg), reflecting mature market dynamics. Top hiring companies are innovative platforms (Vertex: 41 jobs) and medtech (Outset: 21 jobs), not traditional pharma. Salary compression in commercial roles suggests commoditization.
Top Hiring Companies
By Department
Hiring favors medtech and biotech platforms over traditional pharma; medical affairs offers premium compensation but limited volume; commercial roles are abundant but underpaid relative to other therapeutic areas.
On Market (1)
Approved therapies currently available
Competitive Landscape
27 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
Showing 15 of 42 trials with date data
Clinical Trials (42)
Total enrollment: 85,443 patients across 42 trials
Assess the Safety and Efficacy of Nephoxil® in Subjects With End Stage Renal Disease (ESRD) on Dialysis
Use of Tinzaparin for Anticoagulation in Hemodialysis
Conversion From Standard Phosphate Binder Therapy to Fosrenol® (Lanthanum Carbonate) in Chronic Kidney Disease Stage 5
Fibrosis in Renal Allografts
Efficacy and Safety of Fosrenol in Treating Elevated Serum Phosphate Levels in Adults With End Stage Renal Disease
Study to Compare Initial Dosing Parameters of Zemplar in Stage V Chronic Kidney Disease Subjects on Hemodialysis
Phase III Clinical Study of Recombinant Erythropoiesis Stimulating Protein Injection (rESP) in the Treatment of Anemia in Hemodialysis Patients With Chronic Renal Failure
Study Assessing Safety & Effectiveness of a Catheter Lock Solution in Dialysis Patients to Prevent Bloodstream Infection
The Everolimus-Transplant Exit Strategy Trial (E-TEST)
Three Times Weekly (TIW) Growth Hormone Therapy in Children on Hemodialysis
Head to Head Study Against Sevelamer Hydrochloride
Efficacy and Safety of Lanthanum Carbonate and Sevelamer Hydrochloride in Patients Receiving Haemodialysis for End Stage Renal Disease
Efficacy and Tolerability of Treatment With Lanthanum Carbonate in Patients With End Stage Renal Disease Receiving Dialysis
Efficacy and Safety of Lanthanum in Controlling Serum Phosphate Levels in Subjects With End Stage Renal Disease Who Require Treatment for High Levels of Phosphate in Their Blood
A Long Term Study of Lanthanum Carbonate in Patients Requiring Dialysis Who Have Ived Lanthanum Carbonate in Previous Studies Defined by the Protocol.
A Phase II Study to Evaluate the Efficacy of IdeS to Desensitize Transplant Patients With a Positive Crossmatch Test
The Effect of Liraglutide in Patients With Prediabetes and Kidney Failure
A Study to Assess the Pharmacokinetics of Lanthanum Carbonate, Investigate and Compare the Efficacy, Safety and Tolerability of Lanthanum Carbonate With Calcium Carbonate in Hyperphosphataemic Children and Adolescents With Chronic Kidney Disease on Dialysis
A Study in Participants With End-Stage Renal Disease
Effects of Mycophenolate Mofetil (MMF) On Anti-HLA (Human Leukocyte Antigen)Antibody Levels In Patients Awaiting Cadaveric Renal Transplant.
Safety in Immunomodulatory Functions of Alemtuzumab (Campath) in Pediatric Kidney Transplantation Recipients
A Two-Part Phase 2a Study of RVX000222 in Patients With End-Stage Renal Disease Treated With Hemodialysis
A Drug-Drug Interaction Study of Itraconazole and Opevesostat (MK-5684) in Healthy Adult Male Participants (MK-5684-017)
A Study to Evaluate the Effect of MK-5684 in Male Participants With Severe Renal Impairment (RI) and With End-stage Renal Disease (ESRD) (MK-5684-010)
Porcine Kidney Xenotransplantation in Patients With End-Stage Kidney Disease
A Study of LY3113593 in Healthy Participants and Participants With Chronic Kidney Disease Treated With Hemodialysis
Pharmacokinetics, Pharmacodynamics, and Safety Study of Ticagrelor in Hemodialysis Patients and Healthy Subjects
Pharmacokinetics and Safety of Alisporivir in Subjects With End Stage Renal Disease on Hemodialysis Compared to Healthy Subjects
A Study of LY2409021 in Participants With Different Levels of Kidney Function
The Pharmacokinetics of Rocaltrol When Administered Alone or in Combination With Fosrenol or Renvela in Healthy Volunteers
Comparing Absorption of Dietary Phosphorus When Administering FOSRENOL® or RENVELA® in Healthy Adult Volunteers
Pharmacodynamic Study of Two Lanthanum Carbonate Formulations in Healthy Adults
Renal Denervation in End Stage Renal Disease Patients With Refractory Hypertension
Observational Study of BIS in Hemodialysis Patients
Pragmatic Randomised Trial of High Or Standard PHosphAte Targets in End-stage Kidney Disease (PHOSPHATE)
Cardiovascular Risk Comparison Between Expanded Hemodialysis Using Theranova and On-line Hemodiafiltration
Spending and Outcomes for Complex Medicare Advantage Patients
Effect of Lanthanum Carbonate in Patients Previously Treated With Calcium-based Phosphate Binder Therapy
Long-term Effect of Lanthanum Carbonate on Bone
Long Term Treatment of End Stage Renal Disease Patients With Lanthanum Carbonate (Fosrenol)
Correlations Between BNP & Dry Weight, and Between Troponin & Mortality, in Hemodialysis Patients
Evaluation of the Integrated Home Dialysis Model
Related Jobs in Nephrology
Farm Operations Technician
Sr. Research and Development Technician - Pleasanton, CA
Chicago South based Clinical Specialist - Remote, USA
Platform Engineer
Wilmington, NC based Territory Sales Manager - Remote, USA
Statistical Programmer Contractor
Phase Legend
Key Insights
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.